Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far.
It is an accomplishment, after all. The next step is to … keep going.
And why not? Just consider the alternatives.
On that optimistic note, please join us for a needed cup of stimulation. Our choice today is orange creme.
Meanwhile, here are some items of interest to get you going. We hope you have a meaningful and productive day, and conquer the world.
Best of luck… Activist investor Shah Capital plans to vote against the re-election of board nominees and the executive ​compensation package at Novavax’s upcoming annual meeting, renewing pressure for ‌changes at the vaccine maker , Reuters writes. In a letter to the company, hedge fund founder Himanshu Shah said management has failed to implement aggressive cost-cutting measures ​and urged leadership to reduce costs and opportunistically buy back ​10 million to 20 million shares.
Shah Capital, which owns 9% of Novavax and ⁠is its second-largest shareholder, has been pushing the board ​to pursue strategic changes, including a potential sale.
STAT News published a clinical update in Research Highlights on 08 Apr 2026.
The item focuses on STAT+: Pharmalittle: We’re reading about FDA seeking new powers over DTC ads, an EU pledge to fight AMR, and more.
Review the original article for the full source wording and details.